Chemistry Wealth Management LLC increased its position in UnitedHealth Group by 59.2% during the third quarter, acquiring an additional 6,022 shares to bring its total to 16,199 shares. At quarter-end, the holding was valued at $5,593,000 and represented 1.1% of the firm’s overall portfolio, ranking UNH as its 18th largest stake. Other major institutional moves include Norges Bank’s $3.84 billion new stake, Berkshire Hathaway’s $1.57 billion entry, Dodge & Cox’s 117.7% boost to 8.75 million shares worth $2.73 billion, Lone Pine Capital’s $528 million new position and Amundi’s 33.8% increase to 6.19 million shares valued at $1.90 billion. Institutional ownership now accounts for 87.86% of UNH’s outstanding shares.

Seventeen analysts maintain Buy ratings on UnitedHealth Group, nine rate it Hold and three assign Sell. Morgan Stanley raised its price objective from $325 to $395 and reiterated an overweight rating on September 12. Royal Bank of Canada boosted its target from $286 to $408 with an outperform rating on October 29. Goldman Sachs initiated coverage on October 14 with a Buy rating and $406 target. Zacks Research upgraded the rating to Hold on October 6, while UBS lifted its objective from $378 to $430 and affirmed a Buy stance on October 29. The consensus price target stands at $385.54, reflecting a robust outlook for revenue and margin expansion.

In the quarter ended September 30, UnitedHealth Group reported adjusted earnings per share of $2.92, beating the consensus estimate of $2.87, and generated revenue of $113.16 billion, in line with the $113.19 billion forecast and up 12.2% year-over-year. The net margin was 4.04% and return on equity reached 19.23%. On the dividend front, the company declared a quarterly payout of $2.21 per share, equating to an $8.84 annualized distribution and a 2.7% yield, with a 46.1% payout ratio. The dividend was paid on December 16 to shareholders of record as of December 8.